This trial is testing a new cancer treatment combination to see if it is more effective and has fewer side effects than current chemotherapy options for women with ovarian cancer who have not responded to other treatments.
1 Primary · 13 Secondary · Reporting Duration: From baseline up to approximately 44 months
358 Total Participants · 2 Treatment Groups
Primary Treatment: Alpelisib · No Placebo Group · Phase 3
Age 18+ · All Participants · 8 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: